Managing chronic prostate cancer often requires a combination of advanced therapies and medications designed to slow disease progression, relieve symptoms, and improve quality of life. Below is a list of commonly prescribed medications that help provide relief to patients suffering from chronic prostate cancer:
Indenza 40mg Capsule is an anti-cancer medication that contains Enzalutamide, used primarily in the treatment of prostate cancer.
Composition | Enzalutamide 40mg |
Manufacturer | Aprazer Healthcare Pvt Ltd |
Packing | 112 Capsules |
Prescribed For | Prostate Cancer |
Expiry | December 2027 |
Nuparp 300mg Tablet contains Rucaparib, a PARP (poly ADP-ribose polymerase) inhibitor used in the treatment of certain types of cancer, including advanced ovarian and prostate cancers associated with BRCA mutations.
Composition | Rucaparib |
Manufacturer | Zydus Cadila |
Packing | 60 Tablets in a Bottle |
Prescribed For | Prostate Cancer |
Expiry | December 2027 |
Obnyx 40mg contains Enzalutamide, an oral anti-cancer medication used to treat metastatic castration-resistant prostate cancer (mCRPC) and non-metastatic castration-resistant prostate cancer (nmCRPC) in adult men.
Composition | Enzalutamide |
Manufacturer | Zydus Cadila |
Packing | 28 Capsules |
Prescribed For | Prostate Cancer |
Expiry | December 2027 |
Xbira 250 mg and 500 mg tablets contain Abiraterone Acetate, a hormonal therapy used in the treatment of prostate cancer, particularly metastatic castration-resistant prostate cancer (mCRPC).
Composition | Abiraterone Acetate |
Manufacturer | Cipla Ltd |
Packing | 120 Tablets in a Bottle |
Prescribed For | Prostate Cancer |
Expiry | December 2027 |
Zecyte 250mg Tablet contains Abiraterone Acetate, a hormonal therapy used to treat metastatic castration-resistant prostate cancer (mCRPC).
Composition | Abiraterone Acetate |
Manufacturer | Cipla Ltd |
Packing | 120 Tablets in a Bottle |
Prescribed For | Prostate Cancer |
Expiry | December 2027 |
Glenza 40 mg capsule has enzalutamide in it and is used to treat advanced prostate cancer, particularly in men whose cancer does not respond to hormone therapy, regardless of whether it has spread to other parts of the body.
Composition | Enzalutamide |
Manufacturer | Glenmark Pharmaceuticals Ltd |
Packing | 28 Capsules |
Prescribed For | Prostate Cancer |
Expiry | December 2027 |
Enzyl 40mg capsule is an oral anti-cancer medication containing Enzalutamide, primarily used to treat advanced prostate cancer, especially castration-resistant prostate cancer (CRPC).
Composition | Enzalutamide |
Manufacturer | Sun Pharmaceutical Industries Ltd |
Packing | 112 Capsules |
Prescribed For | Prostate Cancer |
Expiry | December 2027 |
Enzana 40mg Capsule contains Enzalutamide, a medication used to treat prostate cancer that has spread or is resistant to standard hormone therapy.
Composition | Enzalutamide |
Manufacturer | Hetero Healthcare Limited |
Packing | 56 Capsules |
Prescribed For | Prostate Cancer |
Expiry | December 2027 |
Enzamide 40 mg contains enzalutamide, a nonsteroidal androgen receptor inhibitor prescribed primarily for castration-resistant prostate cancer (CRPC)—both metastatic (spread beyond the prostate) and non-metastatic forms.
Composition | Enzalutamide |
Manufacturer | Intas Pharmaceuticals Ltd |
Packing | 56 Capsules |
Prescribed For | Prostate Cancer |
Expiry | December 2027 |
Bdron 500mg Tablet contains Abiraterone Acetate, a hormonal therapy used in the treatment of advanced prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC).
Composition | Abiraterone Acetate |
Manufacturer | BDR Pharmaceuticals |
Packing | 60 Tablets |
Prescribed For | Prostate Cancer |
Expiry | December 2027 |
Bdrelin 3.75mg Injection contains Triptorelin, a gonadotropin-releasing hormone (GnRH) agonist used to treat hormone-sensitive conditions such as advanced prostate cancer, endometriosis, uterine fibroids, and central precocious puberty.
Composition | Triptorelin |
Manufacturer | BDR Pharmaceuticals |
Packing | 1 Vial |
Prescribed For | Prostate Cancer |
Expiry | December 2027 |
Bdenza 40mg Capsule contains Enzalutamide, a potent anti-androgen medication used in the treatment of advanced prostate cancer
Composition | Enzalutamide |
Manufacturer | Prakash Biopharma |
Packing | 112 Capsules |
Prescribed For | Prostate Cancer |
Expiry | December 2027 |
Azel 40mg Capsule is a prescription medicine that contains enzalutamide, a powerful androgen receptor inhibitor, and it is mainly prescribed for the treatment of advanced prostate cancer.
Composition | Enzalutamide |
Manufacturer | Dr Reddy’s Laboratories Ltd |
Packing | 112 Capsules |
Prescribed For | Prostate Cancer |
Expiry | December 2027 |
Apnat 60mg Tablet contains Apalutamide, an anti-androgen medication used in the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC).
Composition | Apalutamide |
Manufacturer | Natco Pharma Ltd |
Packing | 120 Tablets |
Prescribed For | Prostate Cancer |
Expiry | December 2027 |
Ahabir 500mg Tablet contains Abiraterone Acetate, a hormonal therapy used in the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Composition | Abiraterone Acetate |
Manufacturer | Hetero Drugs Ltd |
Packing | 120 Tablets |
Prescribed For | Prostate Cancer |
Expiry | December 2027 |
Abirakast 250mg Tablet contains Abiraterone Acetate and is primarily used in the treatment of advanced prostate cancer.
Composition | Abiraterone Acetate (250mg) |
Manufacturer | Aprazer Healthcare Pvt. Ltd. |
Packing | 120 tablets in 1 bottle |
Prescribed For | Prostate Cancer |
Expiry | December 2027 |
Abirapro 250mg Tablet contains Abiraterone Acetate, a hormone therapy used in the treatment of advanced prostate cancer.
Composition | Abiraterone Acetate (250mg) |
Manufacturer | Glenmark Pharmaceuticals |
Packing | 120 tablets in 1 bottle |
Prescribed For | Prostate Cancer |
Expiry | December 2027 |